Mirtazapina Eg Stada (Mirtazapine)

Mirtazapine, the active ingredient in Mirtazapina Eg Stada, is a NaSSA (noradrenergic and specific serotonergic antidepressant) presented as an oral dosage form for oral use. It is indicated for the treatment of major depressive disorder in adult patients and is prescribed by qualified healthcare professionals as a prescription‑only medication.

GNH USA supplies Mirtazapina Eg Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable sourcing, quality assurance and regulatory support to meet global market demands.

Mirtazapine acts on neurotransmitter systems involved in mood regulation, primarily addressing major depressive disorder.

- Major depressive disorder: alleviates depressive symptoms and improves overall mood in adult patients. - Major depressive disorder with insomnia: helps reduce sleep disturbances and promotes restorative sleep. - Major depressive disorder with anxiety: diminishes anxiety symptoms accompanying depression.

Common side effects are generally mild to moderate and may affect treatment tolerability.

Common Side Effects: - Sedation or drowsiness - Increased appetite leading to weight gain - Dry mouth - Constipation - Dizziness - Fatigue

Serious or Rare Side Effects: - Agranulocytosis or severe neutropenia - Severe hypersensitivity reactions (rash, angioedema) - Seizures - Elevated liver enzymes - Suicidal thoughts or behavior - Unexplained bleeding or bruising

Mirtazapine should be used with careful clinical monitoring to ensure safety.

- Monitor weight: watch for rapid weight gain and metabolic changes. - Assess mood: observe for emergence of suicidal thoughts, especially early in therapy. - Evaluate liver function: consider baseline and periodic liver enzyme testing. - Caution in elderly: increased risk of sedation and falls. - Avoid abrupt discontinuation: taper dose to minimize withdrawal symptoms. - Store below 25°C: keep in the original pack, protect from moisture.

Mirtazapine may interact with other medicines, altering its effectiveness or safety.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of serotonin syndrome. - Strong CYP1A2 inhibitors (e.g., fluvoxamine): may increase mirtazapine levels. - CNS depressants (e.g., benzodiazepines, alcohol): additive sedation.

Moderate Interactions (Monitor Closely): - CYP2D6 substrates (e.g., codeine, tamoxifen): possible altered metabolism. - Anticoagulants (e.g., warfarin): monitor coagulation parameters. - Anticholinergic agents: may exacerbate dry mouth and constipation.